#USA #Fremont, California #Alamar Biosciences #Justin McAnear #Todd White

Alamar Biosciences Strengthens Executive Leadership

In a bid to enhance its growth trajectory, Alamar Biosciences has made significant changes to its executive leadership team. The company, which specializes in precision proteomics for early disease detection, has appointed Tod White as President and Justin McAnear as Chief Financial Officer. These strategic moves underscore Alamar's commitment to innovation, operational excellence, and sustainable growth.

Key Appointments

Alamar's Board of Directors has officially promoted Tod White, JD, to the position of President. Since joining Alamar, White has played a pivotal role in the company’s development, contributing extensively to various essential functions including finance, human resources, investor relations, and legal affairs. His promotion reflects not only the Board's recognition of his substantial impact but also their confidence in his ability to guide Alamar through its next transformative phase.

"Tod is a cornerstone of our leadership team," stated Yuling Luo, the founder, Chairman, and CEO of Alamar Biosciences. "His capacity to navigate complexity and drive cross-functional alignment has been critical to our success. This appointment signifies the Board’s trust in Tod’s vision and leadership to expand our operations and deepen our impact."

In complementing White’s appointment, Alamar has welcomed Justin McAnear as the new Chief Financial Officer. McAnear brings over 25 years of extensive leadership experience across various industries, notably participating in the successful IPO of 10x Genomics in 2019 where he served as CFO for over five years. His previous tenure at Tesla as Vice President for Worldwide Finance and Operations equipped him with invaluable experience in managing significant financial initiatives such as the launch of the Model X and Model 3, as well as the acquisition of Solar City. His career milestones include various roles at Apple and JJ, alongside serving over nine years as a Marine officer and pilot.

Luo expressed optimism regarding McAnear’s appointment: "Justin's arrival marks a significant moment for Alamar. He uniquely combines strategic insight, operational discipline, and profound expertise in scaling complex organizations. I look forward to collaborating with him as we continue to grow and evolve the company."

Driving Future Growth

Together, White and McAnear bring complementary strengths to Alamar Biosciences. Their combined expertise will help the company leverage upcoming opportunities and further its mission to pioneer innovations in precision proteomics. Alamar aims to enhance its NULISA™ Platform and ARGO™ HT System, which integrate seamlessly with cutting-edge genomic advancements, achieving unmatched sensitivity in protein detection.

The overarching goal remains clear: to facilitate the earliest possible detection of diseases, thereby improving patient outcomes significantly. Alamar's technologies are designed to surpass current market standards in terms of protein detection capabilities, and with the enhanced leadership, the company is poised to fortify its position at the forefront of the biosciences industry.

About Alamar Biosciences

Alamar Biosciences, Inc. is a privately held biotechnology firm committed to advancing precision proteomics for early disease detection. The company's proprietary platforms demonstrate remarkable sensitivity, thereby delivering unparalleled innovation in the realm of disease diagnostics.

For more details, visit alamarbio.com.